Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement

American Journal of Pathology

Volumn 154, Issue 5, 1999, Pages 1513-1524

  Czermak, Boris J ^a,c   Lentsch, Alex B ^b,c   Bless, Nicolas M ^a   Schmal, Hagen ^a   Friedl, Hans Peter ^a   Ward, Peter A ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL ACTIVATION; CYTOKINE PRODUCTION; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG INJURY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0032933884     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65405-3     Document Type: Article

References (44)

1. Koehl J, Bitter-Suermann D: Anaphylatoxins. Complement in Health and Disease. Edited by K Whaley, M Loos, and JM Weiler. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1993, pp 299-324
2. Craddock PR: Complement, granulocytes, and shock lung. Am J Emerg Med 1984, 2.78-81
3. Duchateau J, Haas M, Schreyen H, Radoux L, Sprangers I, Noel FX, Braun M, Lamy M: Complement activation in patients at risk of developing the adult respiratory distress syndrome. Am Rev Respir Dis 1984, 130:1058-1064
4. Weigelt JA, Chenoweth DE, Borman KR, Norcross JF: Complement and the severity of pulmonary failure. J Trauma 1988, 28:1013-1019
5. Langlois PF, Gawryl MS: Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138: 368-375
6. Langlois PF, Gawryl MS, Zeller J, Lint T: Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: a potential mechanism for pulmonary inflammation. Heart Lung 1989, 18:71-84
7. Frank MM, Fries LF: The role of complement in inflammation and phagocytosis. Immunol Today 1991, 12:322-326
8. Ward PA: Role of complement in lung inflammatory injury. Am J Pathol 1996, 149:1081-1086
9. Mulligan MS, Schmid E, Till GO, Hugli TE, Friedl HP, Roth RA, Ward PA: C5a-dependent upregulation in vivo of lung vascular P-selectin. J Immunol 1997, 158:1857-1861
10. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994, 94:1147-1155
11. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989, 264:9053-9060
12. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS: Enhancement by the complement membrane attack complex of TNFα-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995, 155:1434-1441
13. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS: Sublytic concentrations of the membrane attack complex (MAC) of complement induce endothelial interleukin 8 (IL-8) and monocyte protein 1 (MCP-1) through nuclear factor-κB activation. Am J Pathol 1997, 150:2019-2031
14. Hänsch GM, Seitz M, Betz M: Effect of the late complement component C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol 1987, 82:317-320
15. Johnson KJ, Ward PA: Acute immunologic pulmonary alveolitis. J Clin Invest 1974, 54:349-357
16. Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, Hugli TE, Miyasaka M, Warner RL, Johnson KJ, Ward PA: Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996, 98:503-512
17. Shanley TP, Schmal H, Warner RL, Schmid E, Friedl HP, Ward PA: Requirement for the C-X-C chemokines: MIP-2 and CINC in IgG immune complex-induced lung injury. J Immunol 1997, 158:3439-3448
18. Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA: Role of macrophage inflammatory protein-1α (MIP-1α) in acute lung injury in rats. J Immunol 1995, 154:4793-4802
19. Vogt W, Zimmermann B, Hesse D, Nolte R: Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents. Mol Immunol 1992, 29:251-256
20. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor, tumor necrosis factor from human monocytes. J Immunol Methods 1986, 95:99-105
21. Morgan BP: Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989, 264:1-14
22. Deryckere F, Gannon F: A one hour minipreparation technique for extraction of DNA-binding proteins from animal tissues. BioTechniques 1994, 16:405-410
23. Lentsch AB, Czermak BJ, Bless NM, Ward PA: NF-κB activation during IgG immune complex-induced lung injury: requirements for TNFα and IL-1β but not complement. Am J Pathol 1998, 152:1327-1336
24. Podack ER: Cytolytic Lymphocytes and Complement. Edited by Podack ER, Boca Raton, FL, CRC Press, 1988, pp 173-184
25. Ramm LE, Whitlow MB, Mayer MM: The relationship between channel size and number of C9 molecules in the C5b-9 complex. J Immunol 1985, 134:2594-2599
26. Stewart JL, Monahan JB, Brickner A, Sodetz JM: Measurement of the ratio of the eight and ninth components of human complement on complement-lysed membranes. Biochemistry 1984, 23:4016-4022
27. Morgan BP: Cellular responses to the membrane attack complex. Complement in Health and Disease. Edited by K Whaley, M Loos, JM Weiler. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1993, pp 325-351
28. Driscoll KE, Hassenbein DG, Carter J, Poynter J, Asquith TN: Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung alter mineral dust exposure. Am J Respir Cell Mol Biol 1993, 8:311-318
29. Paine III R, Rolfe MW, Standiford TJ, Burdick MD, Rollins BJ, Strieter RM: MCP-1 expression by rat type II alveolar epithelial cells in primary culture. J Immunol 1993, 150:4561-4570
30. Warner RL, Paine III R, Christensen PJ, Marletta MA, Richards MK, Wilcoxen SE, Ward PA: Lung sources and cytokine requirements for in vivo expression of inducible nitric oxide synthase. Am J Respir Cell Mol Biol 1995, 12:649-661
31. Wetsel RA: Expression of the complement C5a anaphylatoxin receptor (C5aR) on nonmyeloid cells. Immunol Lett 1995, 44:183-187
32. Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI, Morgan EL, Sanderson SD: Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J Immunol 1998, 160:5073-5081
33. Sylvestre DL, Ravetch JV: Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994, 265:1095-1098
34. Cui L, Carney DF, Hugli TE: Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci 1994, 3:1169-1177
35. Murphy HS, Shayman JA, Till GO, Maroughui M, Owens CB, Ryan US, Ward PA: Superoxide responses of endothelial cells to C5a and TNFα: divergent signal transduction pathways. Am J Physiol 1992, 263:L51-L59
36. Henson PM, McCarthey K, Larsen GL, Webster RO, Giclas PC, Dreisin RB, King TE, Shaw JO: Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol 1979, 97:93-110
37. Lentsch AB, Shanley TP, Sarma V, Ward PA: In vivo suppression of NF-κB, and preservation of IκBκ by interleukin-10, and interleukin 13. J Clin Invest 1998, 100:2243-2248
38. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW: In vivo antioxidant treatment suppresses NF-κB activation, and neutrophilic lung inflammation. J Immunol 1996, 157:1630-1637
39. Hohmann HP, Remy R, Poschl B, van Loon APG: Tumor necrosis factors-α and -β bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-κB at low receptor occupancy and within minutes after receptor binding. J Biol Chem 1990, 265:15183-15188
40. Hiscott J, Marois J, Garoufalis J, D'Addario M: Characterization of a functional NF-κB site in the human interleukin 1 β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993, 13:6231-6240
41. Mukaida N, Mahe Y, Matsushima K: Cooperative interaction of NF-κB and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990, 265:21128-21133
42. Mahe Y, Mukaida N, Kuno K, Akiyama M, Ikeda N, Matsushima K, Murakami S: Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on NF-κB, and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 1991, 266:13759-13763
43. Grove M, Plumb M: C/EBP, NF-κB, and c-Ets family members, and transcriptional regulation of the cell-specific, and inducible macrophage inflammatory protein 1 α immediate-early gene. Mol Cell Biol 1993, 13:5276-5289
44. Lentsch AB, Czermak BJ, Bless, Nicolas M, Ward PA: NF-κB activation during IgG immune complex-induced lung injury: requirements for TNFα and IL-1β but not complement. Am J Pathol 1998, 152: 1327-1336